Change in cardiac function: number of patients with EF < 45% · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
It is very uncertain whether prophylactic perindopril (2 mg to 4 mg daily) changes change in cardiac function: number of patients with EF < 45% compared with placebo (very low certainty).
1 finding from 1 review
Change in Ejection fraction (%) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Change in cardiac function (change in peak systolic radial strain in LV lateral wall segments) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Change in cardiac function (change in systolic radial strain rate LV inferolateral wall) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvements in quality of life measures · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Change in cardiac function: change (decline) from baseline in left ventricular strain · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Change in Ejection fraction (%) · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys with DMD and left ventricular ejection fraction 45% or more
1 finding from 1 review
Improvements in quality of life measures · boys with DMD and left ventricular ejection fraction 45% or more
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Size of metabolically abnormal areas of myocardium · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys with DMD and left ventricular ejection fraction 45% or more
It is very uncertain whether eplerenone (25 mg daily) changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Change in Ejection fraction (%) · people with DMD or BMD (ages not stated)
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · people with DMD or BMD (ages not stated)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvements in quality of life measures · people with DMD or BMD (ages not stated)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with DMD or BMD (ages not stated)
1 finding from 1 review
Improvements in quality of life measures · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys with DMD, normal cardiac examination and LVEF > 55% at baseline
Prophylactic perindopril (2 mg to 4 mg daily) showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in cardiac function (change in fractional shortening) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review